利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

164 条记录 (耗时 0.075 秒)

    Pharmaceutical compositions and methods using natriuretic peptides
    93.
    发明授权
    Pharmaceutical compositions and methods using natriuretic peptides 失效

    公开(公告)号：US06974861B2

    公开(公告)日：2005-12-13

    申请号：US10402021

    申请日：2003-03-27

    申请人： J. Jeffrey Seilhamer ,  John Lewicki ,  Robert M. Scarborough ,  J. Gordon Porter

    发明人： J. Jeffrey Seilhamer ,  John Lewicki ,  Robert M. Scarborough ,  J. Gordon Porter

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/22 ,  A61P9/08 ,  A61P9/12 ,  C07K7/08 ,  C07K14/00 ,  C07K14/575 ,  C07K14/58 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/12 ,  C12N15/16 ,  C12P21/02 ,  C12R1/19 ,  C07K17/00

    CPC分类号： C12P21/02 ,  A61K38/00 ,  C07K14/58 ,  C07K14/582 ,  C07K16/241 ,  C07K16/2803 ,  C07K2317/622 ,  G01N33/74

    摘要： The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: R1-Cys-Phe-Gly-Arg- Arg/ - Leu/ -Asp-Arg-                     Lys    Met                                                (1)    Ile- Gly/ -Ser- Leu/ -Ser-Gly-Leu-Gly-Cys-R-2         Ser        Ser wherein R1 is selected from the group consisting of:                                              (H);                                             Gly-;                                         Ser-Gly-;                                   Asp/                                   Lys/ -Ser-Gly-;                                   Gly                            Arg/   Asp/                            His/ - Lys/ -Ser-Gly-;                            Gln    Gly                            Arg/   Asp/                     Met/ - His/ - Lys/ -Ser-Gly-;                     Val    Gln    Gly                            Arg/   Asp/              Thr/ - Met/ - His/ - Lys/ -Ser-Gly-;              Met    Val    Gln    Gly                            Arg/   Asp/         Lys- Thr/ - Met/ - His/ - Lys/ -Ser-Gly-;              Met    Val    Gln    Gly                            Arg/   Asp/     Pro-Lys- Thr/ - Met/ - His/ - Lys/ -Ser-Gly-;              Met    Val    Gln    Gly                            Arg/   Asp/ Ser-Pro-Lys- Thr/ - Met/ - His/ - Lys/ -Ser-Gly-;              Met    Val    Gln    Gly or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human BNP in FIG. 8, or a composite thereof; R2 is (OH), NH2, or NR′R″ wherein R′ and R″ are independently lower alkyl (1-4C) or is Asn/ Lys Asn/ -Val Lys Asn/ -Val-Leu Lys Asn/ -Val-Leu-Arg Lys Asn/ -Val-Leu-Arg- Arg/ Lys                Lys Asn/ -Val-Leu-Arg- Arg/ - Tyr/ Lys                Lys    His or the amides (NH2 or NR′R″) thereof, with the proviso that if formula (1) is R1-Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-    Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R2 and R1 is Asp-Ser-Gly-, R2 cannot be Asn-Val-Leu-Arg-Arg-Tyr. The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.

    Platelet ADP receptor inhibitors
    95.
    发明授权
    Platelet ADP receptor inhibitors 失效
    血小板ADP受体抑制剂

    公开(公告)号：US06667306B1

    公开(公告)日：2003-12-23

    申请号：US09226103

    申请日：1999-01-07

    申请人： Alan M. Laibelman ,  Hans-Michael Jantzen ,  Pamela B. Conley ,  Larry J. Fretto ,  Robert M. Scarborough

    发明人： Alan M. Laibelman ,  Hans-Michael Jantzen ,  Pamela B. Conley ,  Larry J. Fretto ,  Robert M. Scarborough

    IPC分类号： C07D51314

    CPC分类号： C07D513/04

    摘要： The invention relates to novel compounds of formula (I) containing fused heterocyclic ring systems which are effective platelet ADP receptor inhibitors: In formula (I), W is carbon or nitrogen, wherein at least one W is a carbon; and Y is nitrogen, oxygen, or sulfur. Such compounds including pharmaceutically acceptable salts are useful in various pharmaceutical compositions for the prevention and/or treatment of cardiovascular disease particularly those related to thrombosis.

    摘要翻译： 本发明涉及含有作为有效血小板ADP受体抑制剂的稠合杂环体系的式（I）化合物：式（I）中W是碳或氮，其中至少一个W是碳; Y是氮，氧或硫。 包括药学上可接受的盐的这些化合物可用于预防和/或治疗心血管疾病，特别是血栓形成相关的各种药物组合物。

    Nucleic acids encoding the C140 receptor
    97.
    发明授权
    Nucleic acids encoding the C140 receptor 失效
    编码C140受体的核酸

    公开(公告)号：US06297026B1

    公开(公告)日：2001-10-02

    申请号：US08486673

    申请日：1995-06-07

    申请人： Johan Sundelin ,  Robert M. Scarborough

    发明人： Johan Sundelin ,  Robert M. Scarborough

    IPC分类号： C12N1512

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/723 ,  G01N2333/726 ,  G01N2500/00

    摘要： Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.

    摘要翻译： 编码C140细胞表面受体的核酸分子已被克隆并测序。 C140受体DNA的可用性允许重组产生可在细胞表面（包括卵母细胞）上产生的C140受体。 核酸分子可用于检测影响C140受体活性的物质，即受体激动剂或拮抗剂。 此外，阐明C140受体的结构允许设计可用于此类测定中的激动剂和拮抗剂化合物。 C140受体的可用性还允许产生与C140受体的一个或多个抗原表位特异性免疫反应的抗体。